A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy or in Combination With Pembrolizumab (Anti-PD-1 Antibody) in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors | Arctuva